A safety, tolerability, pharmacokinetic and efficacy study of azithromycin plus piperaquine as intermittent presumptive treatment in pregnant Papua New Guinean women

阿奇霉素联合哌喹作为巴布亚新几内亚孕妇间歇性推定治疗的安全性、耐受性、药代动力学和疗效研究

• 批准号: nhmrc : 1036951
• 负责人: Dr Brioni Moore
• 金额: $ 23.05万
• 依托单位: The University of Western Australia
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/safety-tolerability-pharmacokinetic-guinean-women/111038
• 关键词: safety; tolerability; pharmacokinetic; efficacy; study

The purpose of this research is to investigate a new antimalarial combination therapy, azithromycin (AZI) plus piperaquine (PQ), for the prevention of malaria infection in pregnant Papua New Guinean women. It is anticipated that these studies will provide sufficient data to determine if AZI-PQ is a suitable alternative treatment option in PNG, and other countries which have similar malaria epidemiology including the presence of drug resistant parasites.

本研究的目的是探讨一种新的抗疟联合疗法，阿奇霉素（AZI）加哌喹（PQ），用于预防巴布亚新几内亚孕妇疟疾感染。预计这些研究将提供足够的数据，以确定AZI-PQ是否是巴布亚新几内亚和其他具有类似疟疾流行病学（包括存在耐药性寄生虫）的国家的合适替代治疗选择。